SCHEMBL484191

SCHEMBL484191

Cc1cccc(C(=O)O)c1-n1ccc2ccccc21

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FABP4 P15090 1/20 0.44
MYC P01106 1/20 0.44
KDM4E B2RXH2 2/20 0.44
ALDH1A1 P00352 2/20 0.44
HPGD P15428 2/20 0.44
HSD17B10 Q99714 2/20 0.44
NOTUM Q6P988 2/20 0.43
MCL1 Q07820 2/20 0.43
KMT2A Q03164 3/20 0.42
CYP3A4 P08684 2/20 0.42
CYP2C9 P11712 2/20 0.42
NR4A1 P22736 1/20 0.41
NR4A2 P43354 1/20 0.41
NR4A3 Q92570 1/20 0.41
POLB P06746 1/20 0.41
MEN1 O00255 1/20 0.40
AKR1B10 O60218 1/20 0.40
TRPA1 O75762 1/20 0.40
ABCB11 O95342 1/20 0.40
DHFR P00374 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL484192 0.79 MYC (0.46) MYCKDM4EALDH1A1NOTUMMCL1
SCHEMBL27643873 0.79 NOTUM (0.54) MYCNOTUMMCL1KMT2ANR4A1
SCHEMBL2581647 0.79 ALB (0.40) NOTUMMCL1KMT2ANR4A1NR4A2
SCHEMBL16719405 0.77 RAB9A (0.44) NOTUMMCL1KMT2ANR4A1NR4A2
SCHEMBL28436731 0.76 L3MBTL1 (0.56) MYCALDH1A1NOTUMMCL1KMT2A
SCHEMBL3675798 0.76 CDK2 (0.43) MYCNOTUMMCL1KMT2APOLB
SCHEMBL10431254 0.74 HTT (0.47) MYCKMT2AMEN1RAB9ADHODH
SCHEMBL20774911 0.74 ELANE (0.42) FABP4MYCKDM4EALDH1A1HPGD
SCHEMBL16719408 0.74 ACMSD (0.36) MCL1KMT2ANR4A1NR4A2NR4A3
SCHEMBL3685234 0.73 NOTUM (0.43) MYCNOTUMMCL1KMT2ANR4A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10633369-B2 Method of inhibiting DYRK1B 4 SC AG (DE) 2020-04-28 US disclosed
US-20180201606-A1 METHOD OF INHIBITING DYRK1B 4 SC AG (DE) 2018-07-19 US disclosed
US-9951050-B2 Method of inhibiting DYRK1B 4 SC AG (DE) 2018-04-24 US disclosed
US-20140371251-A1 METHOD OF INHIBITING DYRK1B 4SC DISCOVERY GMBH (DE) 2014-12-18 US disclosed
EP-1888595-B1 SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC (CA) 2012-02-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10633369-B2 Method of inhibiting DYRK1B SMO, GLI1, GRK2 FABP4 4443/4885MYC 263/4885KDM4E 996/4885
US-20180201606-A1 METHOD OF INHIBITING DYRK1B SMO, GLI1, GRK2 FABP4 4443/4885MYC 263/4885KDM4E 996/4885
US-20140371251-A1 METHOD OF INHIBITING DYRK1B SMO, GLI1, GRK2 FABP4 4443/4885MYC 263/4885KDM4E 996/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.